Clinical review report: Isavuconazole (Cresemba) (AVIR Pharma Inc.)
The objective of this review is to perform a systematic review of the beneficial and harmful effects of isavuconazole compared with the other available antifungal drugs marketed in Canada for the treatment of invasive aspergillosis or invasive mucormycosis
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
June 2019, 2019
|
| Edition: | Final |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review is to perform a systematic review of the beneficial and harmful effects of isavuconazole compared with the other available antifungal drugs marketed in Canada for the treatment of invasive aspergillosis or invasive mucormycosis |
|---|---|
| Physical Description: | 1 PDF file (75 pages) illustrations |